Interview with CEO Magnus Corfitzen from Ascelia Pharma on latest data on the SPARKLE study.
Interview with CEO Magnus Corfitzen from Ascelia Pharma on latest data from the SPARKLE study.
All 80 patients are now enrolled in the SPARKLE study, a major milestone for the company. The CEO Magnus Corfitzen talk about primary and secondary endpoints and when they expect to release data.
The company holds an ODA(Orphan Drug Designation) what is that and why is that important.
Finally the CEO elaborates on the market potential for Orviglance.
Listen here: ttps://youtu.be/N1Qg83mJ0MM
Disclaimer:
HC Andersen Capital receives payment from Ascelia Pharma for a Digital IR/Corporate Visibility subscription agreement. /ANALYST Claus Thestrup 4:00 PM 03-03-2023.
Ascelia Pharma
Ascelia Pharma is a Swedish biotech company with a focus on orphan oncology treatments. They develop and commercialize novel drugs that address unmet medical needs and have a clear development and market pathway. Currently, Ascelia pharma has two pipeline products, namely Orviglance and Oncoral. Orviglance is a novel contrast agent for MR-Imaging developed to improve the detecting and visualization of focal liver lesions (Including liver metastases – and primary tumors) in patients with reduced kidney function. Oncoral is a daily tablet with an established potent anti-tumor effect – even in difficult to treat cancers with the potential to offer better patient outcomes with improved safety following a daily tablet treatment compared to intravenous high-dose infusions at the hospital. Ascelia Pharma is listed on Nasdaq Small Cap Stockholm with ticker ACE.
Read more on company page